Skip to content


Sirolimus, a member of the mTOR inhibitors class, exerts its therapeutic effects by binding to FKBP-12, a specific protein within cells, forming a protein-drug complex. This complex then binds to mTOR kinase, neutralizing its activity. Given the dysfunctional mTOR pathway in many cancers, targeting mTOR has emerged as a crucial therapeutic strategy. In cancer cells, Sirolimus deactivates the mTOR signaling network, leading to cell death and suppression of protein synthesis, cell proliferation, angiogenesis, and cancer cell spread. This mechanism underscores Sirolimus’s potential as an effective treatment modality in sarcoma therapy.